SEARCH

SEARCH BY CITATION

References

  • Abe Y., Namba H., Zheng Y. and Nawa H. (2009) In situ hybridization reveals developmental regulation of ErbB1-4 mRNA expression in mouse midbrain: implication of ErbB receptors for dopaminergic neurons. Neuroscience 161, 95110.
  • Blum M. (1998) A null mutation in TGF-alpha leads to a reduction in midbrain dopaminergic neurons in the substantia nigra. Nat. Neurosci. 1, 374377.
  • von Bohlen und Halbach O. and Unsicker K. (2009) Neurotrophic support of midbrain dopaminergic neurons, in Development and Engineeringof Dopamine Neurons (PasterkampR. J. et al. , eds.), pp. 7377. Springer Sceince, New York.
  • Casper D., Mytilineou C. and Blum M. (1991) EGF enhances the survival of dopamine neurons in rat embryonic mesencephalon primary cell culture. J. Neurosci. Res. 30, 372381.
  • Cornford E. M. and Cornford M. E. (1986) Nutrient transport and the blood-brain barrier in developing animals. Fed. Proc. 45, 20652072.
  • Engele J. and Bohn M. C. (1991) The neurotrophic effects of fibroblast growth factors on dopaminergic neurons in vitro are mediated by mesencephalic glia. J. Neurosci. 11, 30703078.
  • Fry D. W., Kraker A. J., McMichael A., Ambroso L. A., Nelson J. M., Leopold W. R., Connors R. W. and Bridges A. J. (1994) A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265, 10931095.
  • Futamura T., Toyooka K., Iritani S., Niizato K., Nakamura R., Tsuchiya K., Someya T., Kakita A., Takahashi H. and Nawa H. (2002) Abnormal expression of epidermal growth factor and its receptor in the forebrain and serum of schizophrenic patients. Mol. Psychiatry 7, 673682.
  • Futamura T., Kakita A., Tohmi M., Sotoyama H., Takahashi H. and Nawa H. (2003) Neonatal perturbation of neurotrophic signaling results in abnormal sensorimotor gating and social interaction in adults: implication for epidermal growth factor in cognitive development. Mol. Psychiatry 8, 1929.
  • Gill S. S., Patel N. K., Hotton G. R., O’Sullivan K., McCarter R., Bunnage M., Brooks D. J., Svendsen C. N. and Heywood P. (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9, 589595.
  • Goldstein M. and Deutch A. Y. (1992) Dopaminergic mechanisms in the pathogenesis of schizophrenia. FASEB J. 6, 24132421.
  • González-Hernández T., Afonso-Oramas D. and Cruz-Muros I. (2009) Phenotype, compartmental organization and differential vulnerability of nigral dopaminergic neurons. J. Neural Transm. Suppl. 73, 2137.
  • Hatanaka H. and Arimatsu Y. (1984) Monoclonal antibodies to tyrosine hydroxylase from rat pheochromocytoma PC12h cells with special reference to nerve growth factor-mediated increase of the immunoprecipitable enzymes. Neurosci. Res. 1, 253263.
  • Ho A. and Blum M. (1997) Regulation of astroglial-derived dopaminergic neurotrophic factors by interleukin-1 beta in the striatum of young and middle-aged mice. Exp. Neurol. 148, 348359.
  • Hyman C., Hofer M., Barde Y. A., Juhasz M., Yancopoulos G. D., Squinto S. P. and Lindsay R. M. (1991) BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350, 230232.
  • Iwakura Y., Nagano T., Kawamura M., Horikawa H., Ibaraki K., Takei N. and Nawa H. (2001) N-methyl-D-aspartate-inducedalpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) receptor down-regulation involves interaction of the carboxyl terminus of GluR2/3 with Pick1. Ligand-binding studies using Sindbis vectors carrying AMPA receptor decoys. J. Biol. Chem. 276, 4002540032.
  • Iwakura Y., Piao Y. S., Mizuno M., Takei N., Kakita A., Takahashi H. and Nawa H. (2005) Influences of dopaminergic lesion on epidermal growth factor-ErbB signals in Parkinson’s disease and its model: neurotrophic implication in nigrostriatal neurons. J. Neurochem. 93, 974983.
  • Iwakura Y., Wang Y., Abe Y., Piao Y. S., Shishido Y., Higashiyama S., Takei N. and Nawa H. (2011) Dopamine-dependent ectodomain shedding and release of epidermal growth factor in developing striatum: target-derived neurotrophic signaling (Part 2). J. Neurochem. 118, 5768.
  • Kinugasa Y., Ishiguro H., Tokita Y., Oohira A., Ohmoto H. and Higashiyama S. (2004) Neuroglycan C, a novel member of the neuregulin family. Biochem. Biophys. Res. Commun. 321, 10451049.
  • Lin L. F., Doherty D. H., Lile J. D., Bektesh S. and Collins F. (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260, 11301132.
  • Lindholm P., Voutilainen M. H., Laurén J. et al. (2007) Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 448, 7377.
  • Mizuno M., Malta R. S., Nagano T. and Nawa H. (2004) Conditioned place preference and locomotor sensitization after repeated administration of cocaine or methamphetamine in rats treated with epidermal growth factor during the neonatal period. Ann. N Y Acad. Sci. 1025, 612618.
  • Nawa H. and Takei N. (2006) Recent progress in animal modeling of immune inflammatory processes in schizophrenia: implication of specific cytokines. Neurosci. Res. 56, 213.
  • Piao Y. S., Iwakura Y., Takei N. and Nawa H. (2005) Differential distributions of peptides in the epidermal growth factor family and phosphorylation of ErbB 1 receptor in adult rat brain. Neurosci. Lett. 390, 2124.
  • Rozen S. and Skaletsky H. (2000) Primer3-web 0. 3. 0. Available at: http://primer3.sourceforge.net/.
  • Seeman P. (1993) Schizophrenia as a brain disease. The dopamine receptor story. Arch. Neurol. 50, 10931095.
  • Seroogy K. B., Numan S., Gall C. M., Lee D. C. and Kornblum H. I. (1994) Expression of EGF receptor mRNA in rat nigrostriatal system. Neuroreport 6, 105108.
  • Sibilia M., Steinbach J. P., Stingl L., Aguzzi A. and Wagner E. F. (1998) A strain-independent postnatal neurodegeneration in mice lacking the EGF receptor. EMBO J. 17, 719731.
  • Solbrig M., Fallon J. and Liplin I. (2004) Drawings of some other features of the SN-VTA, including dopamine transporter sites, cannabinoid receptors, and different nuclei and fiber tracts in the SN-VTA, in The Rat Nervous System (PaxinosG., ed.), p. 229. Academic Press, Australia.
  • Takazaki R., Shishido Y., Iwamoto R. and Mekada E. (2004) Suppression of the biological activities of the epidermal growth factor (EGF)-like domain by the heparin-binding domain of heparin-binding EGF-like growth factor. J. Biol. Chem. 279, 4733547343.
  • Threadgill D. W., Dlugosz A. A., Hansen L. A., Tennenbaum T., Lichti U., Yee D., LaMantia C., Mourton T., Herrup K. and Harris R. C. (1995) Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 269, 230234.
  • Tohmi M., Tsuda N., Mizuno M., Takei N., Frankland P. W. and Nawa H. (2005) Distinct influences of neonatal epidermal growth factor challenge on adult neurobehavioral traits in four mouse strains. Behav. Genet. 35, 615629.
  • Ullrich A., Coussens L., Hayflick J. S., Dull T. J., Gray A., Tam A. W., Lee J., Yarden Y., Libermann T. A. and Schlessinger J. (1984) Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309, 418425.
  • Velu T. J., Beguinot L., Vass W. C., Zhang K., Pastan I. and Lowy D. R. (1989) Retroviruses expressing different levels of the normal epidermal growth factor receptor: biological properties and new bioassay. J. Cell. Biochem. 39, 153166.
  • Ventrella L. L. (1993) Effect of intracerebroventricular infusion of epidermal growth factor in rats hemitransected in the nigro-striatal pathway. J. Neurosurg. Sci. 37, 18.
  • Wagner B., Natarajan A., Grünaug S., Kroismayr R., Wagner E. F. and Sibilia M. (2006) Neuronal survival depends on EGFR signaling in cortical but not midbrain astrocytes. EMBO J. 25, 752762.
  • Zscheppang K., Korenbaum E., Bueter W., Ramadurai S. M., Nielsen H. C. and Dammann C. E. (2006) ErbB receptor dimerization, localization, and co-localization in mouse lung type II epithelial cells. Pediatr. Pulmonol. 41, 12051212.